      3 pipa
     21 single
     40 home
      2 familys
<<CONTENT>>
glaxo aims high after profit fall

glaxosmithkline saw its profits fall 9% last year to 62bn 115bn but europes biggest drugmaker says a recovery during 2005 is on the way

cheap copies of its drugs particularly antidepressants paxil and wellbutrin and a weak dollar had hit profits but global sales were up 1% in 2004 the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug chief executive jeanpierre garnier said it had been a difficult year

in early afternoon trade in london the company share price was down 1% at 1218 pence mr garnier said the company had absorbed over 15bn of lost sales to generics but still managing to grow the business the continuing success of our key products means we can now look forward to a good performance in 2005 he said 2005 will also be an important year in terms of research and development pipeline progress however the firm discontinued development of an experimental treatment for obesity known as 771 after disappointing clinical trial results glaxo is relying on new treatments for conditions such as cancer diabetes depression hivaids and allergies to lift the pace of sales growth after several disappointing years
